Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00417703
Status:
COMPLETED
Last Update Posted:
2008-01-24
First Post:
2007-01-03
Brief Title:
Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab
Sponsor:
Oklahoma State University Center for Health Sciences
Organization:
Oklahoma State University Center for Health Sciences
Study Overview
Official Title:
A Prospective Investigation of the Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection With more widespread use of intravitreous injections in patients that may require several injections per year it is important to document the sudden increase in intraocular pressure including the maximum intraocular pressure and the time required for the intraocular pressure to return to baseline This data may be useful in stimulating additional studies to evaluate the long term ocular effects of repeated intravitreous injections
We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection
We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection
Detailed Description:
We will assess the trend of intraocular pressure immediately following intravitreal injection of ranibizumab 05 mg 005 mL by taking serial intraocular pressure readings every five minutes for thirty minutes after injection This study is a prospective descriptive data collection consisting of measuring intraocular pressure immediately following intraocular injection and at 5 10 15 20 25 and 30 minutes following injection of ranibizumab 05 mg
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None